Ipsen announces €25 million investment in Ireland to expand manufacturing of transformative treatment for patients suffering from rare and life-threatening conditions

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
  • Milestone investment will increase capacity at Ipsen Ireland’s manufacturing site in Blanchardstown and enhance the production of vital treatments for patients

Thursday, 24 June: Global biopharmaceutical company Ipsen has today announced a milestone investment in its Irish manufacturing site based in Blanchardstown, Dublin. The €25 million investment will significantly increase the company’s capacity in Ireland to produce vital medical treatment that helps patients suffering from both niche cancers and rare diseases.

This investment is part of Ipsen’s continued growth in the Irish market as a biopharmaceutical leader delivering transformative care across oncology, rare diseases and neuroscience, and with a presence in Dublin for over 30 years. Since 2019, Ipsen has expanded its team in Ireland by over 20%, with 165 employees now working at the Blanchardstown site across research & development (R&D), manufacturing and commercial operations, delivering specialty care Active Pharmaceutical Ingredients (APIs) for patients with rare and underserved conditions.  

Speaking about the investment, Tim Shanahan Vice President of Manufacturing for Ipsen Manufacturing Ireland said,

“Ireland is a very important market for us at Ipsen and that is why we have continued to expand and innovate here for over 30 years since we first established our manufacturing site in Blanchardstown. We have invested €60 million in capital projects in Ireland in the last 5 years and are proud to announce a further €25 million to scale up our manufacturing capacity and enable us to produce even more transformative medicine for patients suffering from rare and life-threatening conditions.

“Our dedicated team at Ipsen Ireland is constantly innovating to deliver positive, life-changing care for patients with underserved conditions. We are confident that this investment and our continued growth in the Irish market, will enable us to continue innovating and working towards better treatment and care for patients who need it most.”

END

This website uses cookies in order to improve the site and user experience. By continuing to use it, you agree to our Privacy Policy.